The Hormone Sensitive Breast Cancer drugs in development market research report provides comprehensive information on the therapeutics under development for Hormone Sensitive Breast Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Hormone Sensitive Breast Cancer. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Hormone Sensitive Breast Cancer and features dormant and discontinued products.
GlobalData tracks nine drugs in development for Hormone Sensitive Breast Cancer by eight companies/universities/institutes. The top development phase for Hormone Sensitive Breast Cancer is preclinical with three drugs in that stage. The Hormone Sensitive Breast Cancer pipeline has eight drugs in development by companies and one by universities/ institutes. Some of the companies in the Hormone Sensitive Breast Cancer pipeline products market are: Pharma Mar, University of Texas Southwestern Medical Center and Genentech USA.
The key targets in the Hormone Sensitive Breast Cancer pipeline products market include Estrogen Receptor 1, Estrogen Receptor Beta, and Estrogen Receptor.
The key mechanisms of action in the Hormone Sensitive Breast Cancer pipeline product include Estrogen Receptor 1 Antagonist with two drugs in Phase I. The Hormone Sensitive Breast Cancer pipeline products include three routes of administration with the top ROA being Intravenous and two key molecule types in the Hormone Sensitive Breast Cancer pipeline products market including Small Molecule, and Monoclonal Antibody Conjugated.
Hormone Sensitive Breast Cancer overview
Estrogen and progesterone promote the growth of some breast cancers, which are called hormone-sensitive (or hormone-dependent) breast cancers. Hormone-sensitive breast cancer cells contain proteins called hormone receptors (estrogen receptors, or ERs, and progesterone receptors, or PRs) that become activated when hormones bind to them. The activated receptors cause changes in the expression of specific genes, which can stimulate cell growth.
For a complete picture of Hormone Sensitive Breast Cancer’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
